secwatch.observer — SEC 8-K summary
======================================

Issuer:     Upstream Bio, Inc. (UPB)
CIK:        0002022626
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-265705
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Upstream Bio Q3 loss $33.7M; VIBRANT Ph2 CRSwNP meets primary endpoint
----------------------------------------------------------------------

- VIBRANT Ph2 met primary endpoint: placebo-adjusted NPS reduction of -1.8 (p<0.0001) at 24 weeks.
- Key secondary endpoints met: 76% reduction in need for surgery/systemic corticosteroids (p=0.03).
- Cash $372.4M as of Sept 30, 2025; expected to fund operations through 2027.
- Net loss $33.7M vs $16.0M YoY; R&D expense rose to $33.0M from $15.4M on verekitug costs.
- VALIANT Ph2 severe asthma top-line due Q1 2026; VENTURE Ph2 COPD enrollment ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022626/000119312525265705/0001193125-25-265705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022626/000119312525265705/upb-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-265705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer